Clinical trials: Liver Cell Carcinoma Non-resectable
Unresectable Hepatocellular Carcinoma
Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
uHCC imposes a substantial disease burden in China and the Asia-Pacific region. Atezo+Bev is an important first-line regimen for patients who have not received prior systemic therapy; however, not all patients achieve adequate…
- Trial name
- NCT07824765
- Where
- China
- Volunteers
- 2,658 people
- Sponsor
- Zhongda Hospital
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Carcinoma, Hepatocellular
Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)
This observational study will use existing real-world data from routine clinical care to describe patients with uHCC who received lenvatinib.
- Trial name
- NCT07849660
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Eisai Inc.
Liver Cancer
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot…
- Trial name
- NCT00589030
- Testing
- brachytherapy, yttrium Y 90 glass microspheres
- Where
- United States
- Sponsor
- City of Hope Medical Center
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
Hepatocellular Carcinoma
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
The purpose of this study is to compare the overall survival (OS) for Orantinib in combination with transcatheter arterial chemoembolization (TACE) versus placebo in combination with TACE in patients with unresectable…
- Trial name
- ORIENTAL (NCT01465464)
- Testing
- Orantinib (TSU-68)
- Where
- 6 sites in Japan, South Korea and 1 more
- Volunteers
- 888 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Esophageal Cancer, Gastric Cancer
Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the…
- Conditions
- Esophageal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00537121
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death worldwide.
- Conditions
- Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
- Trial name
- NCT06485466
- Testing
- TACE plus camrelizumab and apatinib, Camrelizumab and apatinib
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Guohui Xu
Liver Cancer
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
RATIONALE: Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01005199
- Testing
- everolimus, sorafenib tosylate
- Where
- 15 sites in Austria, Hungary and 1 more
- Volunteers
- 106 people
- Sponsor
- Swiss Cancer Institute
Unresectable Hepatocellular Carcinoma
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma.
- Trial name
- NCT05096715
- Testing
- Atezolizumab, Bevacizumab, Stereotactic body radiation therapy (SBRT)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Unresectable Hepatocellular Carcinoma
Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer
This study reviewed real-world outcomes of patients with unresectable hepatocellular carcinoma who received lenvatinib-based treatment.
- Trial name
- NCT07298538
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC)
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with…
- Trial name
- EMERALD-Y90 (NCT06040099)
- Testing
- Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE)
- Where
- 21 sites in United States
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
This phase II trial tests how well giving Y-90 radioembolization, durvalumab, tremelimumab and zanzalintinib works for the treatment of hepatocellular carcinoma that cannot be removed by surgery (unresectable) and that has spread…
- Conditions
- Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT07511504
- Testing
- Angiogram, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Unresectable Hepatocellular Carcinoma, Undergoing Chemoembolization and Radioembolization
TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)
The purpose of this research study is to evaluate the quantitative information of utilizing C-arm systems in liver tumor care in hopes this potential clinical combination of imaging could aid in diagnosis and evaluation of tumor…
- Trial name
- TACE (NCT02093104)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Patients suffering from advanced stage hepatocellular carcinoma (HCC) who have shown disease progression during lenvatinib-based first line treatment, will be enrolled in this trial.
- Trial name
- NCT04511455
- Testing
- Cabozantinib
- Where
- 10 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma (HCC)
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY® in patients with unresectable hepatocellular…
- Trial name
- NCT06841185
- Testing
- HLX13, US-sourced YERVOY®, EU-sourced YERVOY®
- Volunteers
- 656 people
- Sponsor
- Shanghai Henlius Biotech
Hepatocellular Carcinoma
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular…
- Trial name
- ZENOBIA (NCT06698250)
- Testing
- Zanzalintinib, Durvalumab, Tremelimumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Anwaar Saeed
Hepatocellular Carcinoma
Transarterial Ethanol Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC)
The objective of this trial was to evaluate the clinical outcome, treatment toxicity and tumor response of TEA for unresectable HCC.
- Trial name
- NCT01837381
- Testing
- TEA
- Where
- 3 sites in Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Solid Tumours
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab…
- Trial name
- IMFINZI-subQ (NCT07391670)
- Testing
- SC durvalumab + rHu, IV durvalumab, Tremelimumab
- Where
- 19 sites in Australia, Georgia and 3 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca